ERBB2 and breast cancer: A subgroup analysis of Asian patients, however, who represented nearly 40% of the study participants, did demonstrate an improvement in survival with ADC therapy among Asian patients with ERBB2-low metastatic BC.44 Certainly, the interaction among race and ethnicity, tumor biology, and outcomes is complex and warrants further study.